Segment Results (Additional Selected Financial Information For Reportable Segments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Total depreciation expense	$ 106,858	$ 59,898	$ 42,665
Total amortization expense	876,451	561,302	218,712
U.S. Branded Pharmaceuticals
Segment Reporting Information [Line Items]
Total amortization expense	554,581	223,367	95,042
U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Total amortization expense	261,235	280,954	78,890
International Pharmaceuticals
Segment Reporting Information [Line Items]
Total amortization expense	60,635	56,981	44,780
Operating Segments | U.S. Branded Pharmaceuticals
Segment Reporting Information [Line Items]
Total depreciation expense	79,839	29,193	16,751
Operating Segments | U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Total depreciation expense	16,294	19,884	16,209
Operating Segments | International Pharmaceuticals
Segment Reporting Information [Line Items]
Total depreciation expense	2,557	3,147	1,856
Corporate unallocated
Segment Reporting Information [Line Items]
Total depreciation expense	$ 8,168	$ 7,674	$ 7,849